Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ali, S. M.
Right arrow Articles by Lipton, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ali, S. M.
Right arrow Articles by Lipton, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:455-459, 2004
© 2004 European Society for Medical Oncology

Original Paper

Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis

Received 10 June 2003; revised 2 October 2003; accepted 7 November 2003;

Background:

There is significant heterogeneity in survival of patients with metastatic breast cancer who have bone-only metastasis. We studied the correlation of serum N-telopeptide (NTx), a marker of bone resorption, and its correlation with clinical outcomes in patients with metastatic breast cancer with bone-only or bone plus soft tissue metastasis.

Patients and methods:

Serum was taken from 250 metastatic breast cancer patients with bone-only or bone plus soft tissue metastasis who participated in two similar randomized studies of second-line hormone therapy. An enzyme-linked immunosorbent assay specific for NTx of type I bone collagen was used to detect serum levels.

Results:

Sixty patients (24%) had elevated serum NTx levels, using the mean + 2 standard deviations (26 nanomoles Bone Collagen Equivalents per liter) of healthy women as a cut-off. The median duration of clinical benefit was significantly shorter in the group with elevated serum NTx levels compared with the group that had normal serum NTx levels (P = 0.0004). Time to progression (TTP) was also significantly shorter in the patients with elevated serum NTx at 139 days compared with 220 days (P = 0.0006). Median survival was also significantly shorter in patients with elevated baseline serum NTx levels at 663 days compared with 941 days (P <0.0001).

Conclusion:

In this study, breast cancer patients with bone-only or bone plus soft tissue metastasis and elevated serum NTx levels have a shorter duration of clinical benefit, TTP and overall survival.

S. M. Ali1,*, L. M. Demers2, K. Leitzel2, H. A. Harvey2, D. Clemens3, N. Mallinak3, L. Engle2, V. Chinchilli2, L. Costa4, C. Brady5, J. Seaman5 and A. Lipton2

1 VA Medical Center, Lebanon, PA; 2 The M. S. Hershey Medical Center, The Pennsylvania State University, Hershey, PA; 3 Ostex International, Seattle, WA; 5 Novartis Pharmaceutical Corp., East Hanover, NJ, USA; 4 Unidade de Oncologia, Hospital de Santa Maria, Lisbon, Portugal

Key words: bone-only metastasis, bone plus soft tissue metastasis, metastatic breast cancer, serum NTx, survival


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
Y. Zheng, H. Zhou, J. R.K. Modzelewski, R. Kalak, J. M. Blair, M. J. Seibel, and C. R. Dunstan
Accelerated Bone Resorption, Due to Dietary Calcium Deficiency, Promotes Breast Cancer Tumor Growth in Bone
Cancer Res., October 1, 2007; 67(19): 9542 - 9548.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S.-H. Tsai, C.-Y. Chen, C.-H. Ku, A. J. Janckila, L. T. Yam, J.-C. Yu, K.-W. Chuang, and T.-Y. Chao
The Semiquantitative Bone Scintigraphy Index Correlates With Serum Tartrate-Resistant Acid Phosphatase Activity in Breast Cancer Patients With Bone Metastasis
Mayo Clin. Proc., August 1, 2007; 82(8): 917 - 926.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Clemons, G. Dranitsaris, W. S. Ooi, G. Yogendran, T. Sukovic, B. Y.L. Wong, S. Verma, K. I. Pritchard, M. Trudeau, and D. E.C. Cole
Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy
J. Clin. Oncol., October 20, 2006; 24(30): 4895 - 4900.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. N. Lara Jr., W. M. Stadler, J. Longmate, D. I. Quinn, J. Wexler, M. Van Loan, P. Twardowski, P. H. Gumerlock, N. J. Vogelzang, E. E. Vokes, et al.
A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
Clin. Cancer Res., March 1, 2006; 12(5): 1556 - 1563.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.